Last updated: August 25, 2026
Sodium sulfate, potassium sulfate, and magnesium sulfate are used primarily as osmotic bowel-cleansing agents before colonoscopy. The combination has two established U.S. dosage-form strategies: the liquid oral solution SUPREP and the tablet product SUTAB. Excipient selection determines taste, tolerability, tablet size, dissolution, electrolyte exposure, packaging, and the commercial position against polyethylene glycol and lower-volume bowel-preparation products.
The strongest commercial opportunity is a differentiated oral solid or concentrated liquid that improves adherence without increasing renal, cardiac, or electrolyte risk. The principal technical barriers are high salt loading, intense salinity and bitterness, rapid dissolution requirements, moisture sensitivity, dose burden, and the need to demonstrate complete bowel cleansing.
What products contain sodium sulfate, potassium sulfate, and magnesium sulfate?
The combination is marketed in the United States in liquid and tablet formulations.
| Product |
Dosage form |
U.S. sponsor |
FDA approval |
Primary use |
| SUPREP Bowel Prep Kit |
Concentrated oral solution diluted with water |
Braintree Laboratories |
2010 |
Colonoscopy preparation |
| SUTAB |
Oral tablets taken with water |
Braintree Laboratories |
2020 |
Colonoscopy preparation |
SUTAB contains, per tablet, approximately 1.479 grams of sodium sulfate, 0.225 grams of potassium sulfate, and 0.188 grams of magnesium sulfate. A complete regimen uses 24 tablets, divided into two 12-tablet doses, with substantial additional water intake. The total active salt mass is approximately 45 grams per full regimen.
SUPREP uses a concentrated liquid that is diluted before administration. Its active ingredients per 6-ounce bottle are approximately 17.5 grams of sodium sulfate, 3.13 grams of potassium sulfate, and 1.6 grams of magnesium sulfate. The standard package contains two bottles for the complete preparation regimen.[1,2]
These products are not interchangeable from a formulation perspective. The liquid platform must solve taste, acidity, preservative compatibility, and dilution issues. The tablet platform must solve compressibility, tablet size, friability, disintegration, dissolution, and swallowability.
What excipients are used in SUTAB tablets?
SUTAB uses a relatively compact excipient system designed for high active loading. The FDA label identifies colloidal silicon dioxide, crospovidone, and magnesium stearate as inactive ingredients.[1]
| Excipient |
Primary function in SUTAB |
Commercial formulation role |
| Colloidal silicon dioxide |
Glidant and flow aid |
Improves powder flow during high-load tablet compression |
| Crospovidone |
Superdisintegrant |
Promotes rapid tablet breakup and active release |
| Magnesium stearate |
Lubricant |
Reduces tooling adhesion and ejection force |
The limited excipient count is commercially relevant. Every additional excipient increases tablet mass and may impair swallowability. The formulation therefore depends on process control rather than a large multifunctional excipient platform.
Why crospovidone is important
The active salts are highly water soluble, but high solubility does not guarantee rapid tablet disintegration. A compressed tablet with a high inorganic-salt fraction can form a dense matrix or exhibit poor liquid penetration. Crospovidone creates a rapid liquid-ingress pathway without substantial gelling.
Alternative disintegrants such as croscarmellose sodium and sodium starch glycolate could be evaluated, but each changes the product's swelling, viscosity, sodium burden, and dissolution profile. Crospovidone is attractive because it provides rapid disintegration at relatively low loading and does not create the pronounced gel layer associated with some swellable polymers.
Why magnesium stearate requires control
Magnesium stearate improves manufacturability but can slow wetting when over-lubrication occurs. The risk is greater in a formulation that must deliver a large mineral-salt load quickly. Mixing time, lubricant concentration, specific surface area, and shear history should be treated as critical process parameters.
Potential alternatives include sodium stearyl fumarate and stearic acid-based systems. Sodium stearyl fumarate can reduce hydrophobicity relative to magnesium stearate, but it may change ejection behavior and tablet mechanical strength. A substitution would require comparative dissolution, disintegration, stability, and bioequivalence work.
What excipients are used in SUPREP oral solution?
SUPREP is a concentrated aqueous formulation containing acidulants, a preservative, and a high-intensity sweetener. The FDA label identifies citric acid, malic acid, sodium benzoate, sucralose, and water as inactive ingredients.[2]
| Excipient |
Function |
Key development consideration |
| Citric acid |
Acidulant and flavor modifier |
Controls pH and contributes to sourness |
| Malic acid |
Acidulant and flavor modifier |
Modifies acid profile and taste duration |
| Sodium benzoate |
Preservative |
Requires preservative efficacy and compatibility control |
| Sucralose |
Sweetener |
Reduces perceived bitterness and salinity |
| Purified water |
Vehicle |
Requires microbial and chemical quality control |
The solution's excipient strategy does not eliminate the dominant sensory problem: sulfate salts produce strong salty, bitter, and mineral notes. Sweetener and acidulation can make the product more acceptable, but excessive sweetness or acidity may increase nausea and reduce adherence.
Commercial development should focus on taste masking rather than simple sweetness escalation. Relevant approaches include:
- Flavor systems with citrus, berry, or tropical profiles.
- Encapsulated flavors that release after dilution.
- Bitter-blocking or taste-modifying agents.
- Low-volume concentrates administered through a measured dosing cup.
- Separate flavor sachets that allow patient customization.
- Ready-to-drink formats that avoid preparation errors.
Any taste-masking system must remain compatible with the active salts, preservative system, pH, container closure, and stability profile.
What formulation strategies can improve patient adherence?
The core adherence problem is the combination of high electrolyte load, nausea, abdominal discomfort, and large water requirements. A commercially attractive product must improve at least one of these factors without reducing cleansing efficacy.
Lower tablet burden
SUTAB requires 24 tablets per complete regimen. Reducing tablet count would require higher-strength tablets, multilayer tablets, or granulation and densification technologies. The commercial benefit is clear, but larger tablets create a direct swallowability tradeoff.
Potential approaches include:
- Higher-density direct compression.
- Wet or dry granulation to improve mechanical strength.
- Multilayer tablets separating salts from taste-masking components.
- Mini-tablets administered in a capsule or multiparticulate format.
- Effervescent tablets that disperse the salts in water before ingestion.
An effervescent product could reduce swallowing burden but would introduce acid-base compatibility, carbon dioxide generation, moisture sensitivity, packaging, and dose-uniformity issues.
Improve liquid taste
The liquid product has a lower swallowing burden but requires dilution and consumption of additional water. A next-generation liquid could use:
- A smaller active concentrate volume.
- A two-chamber package separating flavor from the salt concentrate.
- An oral powder for reconstitution.
- A unit-dose bottle with a calibrated water fill line.
- A flavor-on-demand system.
The formulation must maintain acceptable osmolality and avoid precipitation during storage or dilution.
Address renal and cardiovascular risk
The labels for sulfate-based bowel preparations warn about fluid and electrolyte abnormalities, including hypermagnesemia, hyperkalemia, hypokalemia, hyponatremia, hypernatremia, and renal impairment. Patients with renal disease, heart failure, dehydration, or relevant medication exposure require careful evaluation.[1,2]
An excipient cannot remove the intrinsic electrolyte burden. Commercial differentiation is more likely to come from dosing instructions, hydration support, patient screening, and risk-management materials than from a conventional inactive ingredient.
What regulatory pathways apply to new sulfate bowel-preparation products?
A product containing the same active ingredients can pursue different regulatory strategies depending on its relationship to an approved reference product.
| Development strategy |
Likely FDA pathway |
Main evidence burden |
| Same active ingredients, same dosage form and route |
ANDA under section 505(j) |
Pharmaceutical equivalence, bioequivalence, quality, labeling |
| New tablet or liquid composition with clinical differentiation |
505(b)(2) NDA |
Bridging studies plus clinical or pharmacology support as needed |
| New excipient or novel delivery system |
505(b)(2) or full NDA |
Safety, CMC, comparative performance, and potentially clinical data |
| New indication or materially different dosing regimen |
NDA or supplemental NDA |
Efficacy, safety, and bowel-cleansing endpoint data |
| Compounded preparation |
State and federal compounding framework |
Does not provide the same market authorization as an FDA-approved product |
A generic tablet would need to demonstrate equivalence to the relevant reference product, not simply match the three active ingredients. Differences in inactive ingredients may be acceptable if they do not affect performance, safety, or labeling. A 505(b)(2) product could support a differentiated formulation, but the sponsor would need to establish why the new dosage form provides a meaningful benefit.
The FDA-approved products are prescription bowel preparations, not biologics. Biosimilar regulation therefore does not apply. Competition will come from generic oral solutions, tablets, powders, and alternative active-ingredient combinations.
What patents protect sulfate bowel-preparation products?
Patent analysis must distinguish composition, formulation, manufacturing, packaging, and method-of-use claims.
| Claim category |
Potentially protected subject matter |
Commercial impact |
| Composition |
Specific sulfate ratios and active concentrations |
Can block close copies of the formulation |
| Tablet formulation |
Salt loading, disintegrant, lubricant, granulation, hardness, dissolution |
Relevant to SUTAB-style oral solids |
| Liquid formulation |
pH, acid system, sweetener, preservative, flavor, concentration |
Relevant to SUPREP-style solutions |
| Dosing method |
Split-dose administration and hydration schedule |
May affect labeling and design-around strategy |
| Manufacturing |
Granulation, compression, coating, or packaging process |
Can raise process-transfer and scale-up barriers |
| Container closure |
Moisture-barrier packaging and unit-dose configurations |
Important for tablets and effervescent products |
The Orange Book should be reviewed by NDA number and product name for current listed patents and regulatory exclusivity. FDA product labeling identifies the approved composition and use but does not provide a complete freedom-to-operate analysis.[1-4]
A competitor should evaluate four separate risks:
- Whether the proposed active ratio falls within a listed composition claim.
- Whether the excipient system or manufacturing process is claimed.
- Whether the proposed indication or dosing instructions implicate method-of-use claims.
- Whether a Paragraph IV certification is required for an ANDA.
When would a Paragraph IV challenge arise?
An ANDA applicant may file a Paragraph IV certification when it asserts that a listed patent is invalid, unenforceable, or not infringed. The NDA holder may sue within the statutory period, potentially creating a 30-month stay of approval under the Hatch-Waxman framework.[5]
For sulfate bowel preparations, litigation exposure is likely to depend more on formulation and dosage-form claims than on the basic use of sulfate salts for bowel cleansing. The active ingredients are established osmotic agents, so broad claims covering the ingredients alone may be difficult to sustain unless they contain specific ratios, concentrations, or technical limitations.
How strong is the patent estate for SUTAB and SUPREP?
The commercial strength of an estate depends on claim breadth, expiration timing, Orange Book listing, formulation difficulty, and the availability of practical design-arounds.
SUTAB
SUTAB's main barrier is the high-load tablet platform. A competitor may reproduce the active ingredients but still face development challenges involving:
- Tablet size and patient acceptability.
- Rapid disintegration.
- Mechanical strength during packaging and shipping.
- Moisture protection.
- Dose uniformity across 24 tablets.
- Bioequivalence or comparative clinical performance.
The most defensible claims would generally be those tied to specific formulation ratios, excipient ranges, dissolution behavior, manufacturing parameters, or regimen performance. A competitor could attempt to design around those claims with a different disintegrant, granulation process, tablet architecture, or multiparticulate dosage form.
SUPREP
SUPREP's liquid platform is easier to reproduce at the manufacturing level but more exposed to sensory design-around. A generic or 505(b)(2) competitor could use a different acidulant blend, sweetener, flavor system, preservative, or container format.
The strongest commercial protection may therefore come from brand recognition, physician familiarity, packaging, patient instructions, and evidence of tolerability rather than from a broad excipient claim alone.
What commercial opportunities exist for excipient suppliers?
Excipient suppliers can participate through performance improvements rather than simple ingredient substitution.
High-value excipient opportunities
| Opportunity |
Candidate excipient or technology |
Value proposition |
| Faster tablet breakup |
Crospovidone, optimized co-processed disintegrants |
Lower disintegration time at high salt loading |
| Better powder flow |
Colloidal silica, specialty flow aids |
Higher compression throughput and dose uniformity |
| Lower lubricant impact |
Sodium stearyl fumarate or engineered lubricants |
Better wetting and dissolution |
| Taste masking |
Bitter blockers, encapsulated flavors, ion-exchange systems |
Improved liquid acceptability |
| Moisture control |
High-barrier blister films and desiccant systems |
Longer tablet stability |
| Reconstitution control |
Effervescent systems and soluble flavor platforms |
Reduced patient preparation errors |
| Patient-specific flavoring |
Separate flavor sachets |
Commercial differentiation without reformulating the active concentrate |
Co-processed excipients could be particularly valuable if they improve flow and compressibility without adding substantial tablet mass. The formulation space is constrained because many conventional fillers are unsuitable. Lactose, microcrystalline cellulose, mannitol, and dibasic calcium phosphate could improve compression, but each would increase tablet size or alter dissolution.
How does this product compare with polyethylene glycol bowel preparations?
Sulfate-based preparations compete primarily on volume, regimen burden, tolerability, and cleansing quality.
| Attribute |
Sulfate tablet product |
Sulfate liquid product |
PEG-electrolyte solution |
| Primary advantage |
Avoids drinking a large active solution volume |
Lower active concentrate volume |
Long clinical history and electrolyte-balanced designs |
| Main burden |
24-tablet regimen plus water |
Strong taste and dilution requirements |
Large liquid volume |
| Excipient focus |
Disintegration, flow, lubrication, moisture control |
Flavor, acidulation, preservation, sweetness |
Electrolyte balance, flavor, viscosity |
| Differentiation route |
Fewer tablets, smaller tablets, faster regimen |
Better taste and simplified preparation |
Lower volume and improved palatability |
| Key safety issue |
Electrolyte and fluid shifts |
Electrolyte and fluid shifts |
Fluid burden and electrolyte considerations |
A new sulfate product must offer a measurable adherence advantage. A modest flavor improvement may be insufficient if the product still requires a high tablet count or extensive water intake.
What manufacturing and intellectual-property barriers affect market entry?
Manufacturing barriers are meaningful even when the ingredients are inexpensive.
Tablet manufacturing
The active salts represent most of the tablet mass. This creates challenges in:
- Segregation during blending.
- High compression force.
- Punch and die wear.
- Capping and lamination.
- Lubricant sensitivity.
- Dust control.
- Packaging line throughput.
- Moisture uptake.
A robust process may require dry granulation, roller compaction, specialized tooling, or a controlled compression profile. These process choices can create trade-secret value even when patent protection is limited.
Liquid manufacturing
The liquid concentrate requires control of:
- Salt solubility at the target concentration.
- pH and acidulant balance.
- Preservative efficacy.
- Flavor stability.
- Container compatibility.
- Microbial quality.
- Dilution behavior.
A concentrated solution may crystallize or change flavor during storage. A formulation that remains clear and palatable across the labeled shelf life has a stronger commercial position.
Geographic coverage
U.S. patent and regulatory rights do not establish protection in Europe, Japan, China, Canada, or other markets. International opportunities depend on local regulatory classification, patent families, national-phase status, and reimbursement. The same formulation may require different flavor systems, package labeling, or dosing instructions by market.
What generic launch risks exist?
Generic entry can occur through several routes:
- A direct ANDA for the tablet product.
- An ANDA for the oral solution.
- A 505(b)(2) product with a redesigned dosage form.
- A competing bowel-preparation combination using different osmotic salts.
- A lower-cost product marketed outside the exact branded formulation.
The highest-risk launch scenario for the incumbent is a generic that matches the active ingredients and dosage regimen while using a materially different excipient system. The highest-risk scenario for a challenger is failure to demonstrate equivalent bowel cleansing or unacceptable tolerability despite pharmaceutical similarity.
The brand holder's strongest defenses are likely to include listed patents, regulatory exclusivity where applicable, manufacturing know-how, physician adoption, and patient-compliance data.
What licensing and partnership opportunities exist?
Licensing opportunities are most credible in four areas:
- A specialty excipient platform for high-load oral solids.
- A taste-masking technology compatible with sulfate concentrates.
- A high-barrier package for moisture-sensitive tablets.
- A regional commercialization or manufacturing agreement.
An excipient company could license a co-processed salt-tablet platform to a generic manufacturer. A contract development and manufacturing organization could offer a complete 505(b)(2) package, including formulation, stability, packaging, and clinical bridging support.
A branded company could also license a lower-tablet-count formulation, a ready-to-drink liquid, or a patient-selectable flavor platform. The commercial value would depend on demonstrated adherence, not only laboratory taste scores.
What revenue exposure and market opportunities matter?
Revenue exposure is concentrated in colonoscopy volume, physician prescribing, payer coverage, and competition from generic and alternative bowel preparations. The product is procedure-linked, so demand is less discretionary than for symptomatic over-the-counter products but remains sensitive to screening rates and healthcare utilization.
The main commercial opportunities are:
- Premium tablets for patients who reject high-volume liquids.
- Lower-volume liquid concentrates.
- Generic versions with lower manufacturing cost.
- Hospital and ambulatory-surgery-center contracts.
- International licensing.
- Pediatric or special-population formulations, subject to separate clinical and regulatory requirements.
- Packaging that reduces dosing errors.
- Digital adherence tools linked to split-dose instructions.
A successful reformulation should quantify a benefit such as fewer tablets, lower total water burden, higher completion rate, reduced nausea, or improved cleansing scores.
Key Takeaways
- Sodium sulfate, potassium sulfate, and magnesium sulfate are established bowel-preparation actives marketed in SUPREP liquid and SUTAB tablet products.
- SUTAB relies on a compact excipient system centered on colloidal silicon dioxide, crospovidone, and magnesium stearate.
- SUPREP uses citric acid, malic acid, sodium benzoate, sucralose, and water to manage acidity, preservation, and taste.
- The most valuable formulation opportunities involve taste masking, tablet-burden reduction, rapid disintegration, moisture protection, and simplified dosing.
- Generic and 505(b)(2) developers face technical barriers even when the active ingredients are well known.
- Patent analysis should cover composition, formulation, manufacturing, method of use, packaging, Orange Book listings, and Paragraph IV exposure.
- Biosimilar risk does not apply because the products are small-molecule sulfate bowel preparations.
- Excipient suppliers can create commercial value through co-processed high-load tablet systems, specialty lubricants, taste-masking platforms, and high-barrier packaging.
Frequently Asked Questions
What is the active ingredient in SUTAB?
SUTAB contains sodium sulfate, potassium sulfate, and magnesium sulfate. It is an osmotic bowel-cleansing tablet used before colonoscopy.[1]
Is SUPREP the same as SUTAB?
No. Both contain the same three sulfate salts, but SUPREP is a concentrated oral solution and SUTAB is a tablet regimen. Their excipients, dosing instructions, manufacturing processes, and patent risks differ.
Can a new excipient be used in a generic sulfate bowel preparation?
Yes, if the formulation satisfies applicable FDA requirements and the excipient does not compromise pharmaceutical equivalence, bioequivalence, safety, stability, or labeling. A novel excipient may increase regulatory and development requirements.
Are sulfate bowel preparations biologics?
No. They are small-molecule drug products. A competing product would generally use an ANDA, 505(b)(2), or NDA pathway rather than the biosimilar pathway.
What is the best commercial position for a new sulfate bowel-preparation product?
The strongest position is a product that materially reduces patient burden through fewer tablets, lower water volume, improved taste, simpler dilution, or better regimen completion while maintaining effective cleansing and acceptable electrolyte safety.
References
-
U.S. Food and Drug Administration. (2020). SUTAB prescribing information. Braintree Laboratories, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213185s000lbl.pdf
-
U.S. Food and Drug Administration. (2010). SUPREP Bowel Prep Kit prescribing information. Braintree Laboratories, Inc. https://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022372s000lbl.pdf
-
U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
-
U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations, Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
-
U.S. Food and Drug Administration. (2024). ANDA submissions: Content and format. https://www.fda.gov/drugs/guidance-compliance-regulatory-information/guidances-drugs
